THOUGHT PIECE: BREXIT: Minding the EU’s New Gap

In late June, BREXIT transformed from a hypothetical ‘what-if’ scenario to a sobering reality literally overnight. As many in the UK experienced elation (tinged with perhaps some regret) due to BREXIT, many more in the UK, EU, and affected countries across the globe are overwhelmed by disappointment, apprehension, and most discernibly uncertainty. While the immediate effect was on stark display within global capital markets, the longer-term impact may be most tangibly demonstrated through systemic shifts in policy and process around the world. Until then, the legal and policy gaps will gradually be filled – the exact details of which will begin to shape a new reality for doing business as a pharmaceutical or biopharmaceutical manufacturer in the UK and EU.

Read our entire thought piece on the impact of BREXIT on the European healthcare industry. Email for a copy.